The updated Phase 2 data from Oncolytics Biotech's BRACELET-1 trial shows a significant reduction in disease progression risk and an increased overall response rate with the pelareorep-paclitaxel combination compared to paclitaxel monotherapy. This positive news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates the potential effectiveness of their treatment for metastatic breast cancer.